Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-PsA 1 phase 3 trial of upadacitinib versus placebo and adalimumab in active psoriatic arthritis
MOH_2017-11-01_000410Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in psoriatic arthritis (PsA) (7 arms), sponsored by AbbVie Inc. Started Sep 2017; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on MOH_2017-11-01_000410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-01_000410.